ArticleClinical kidney journal2025
Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients. Methods: This retrospective hospital-based cohort study enrolled patients with CKD stage 3-5 between 1 January 2011 and 30 June 2023. The patients were classified as spironolactone users or nonusers, with each user matched to two nonusers by propensity scores. The outcomes of interest included ESRD, MACE, all-cause mortality and severe hyperkalemia. MACE include nonfatal stroke, nonfatal myocardial infarction and cardiovascular death. Results: After propensity score matching, 2711 spironolactone users and 5422 nonusers were included in this analysis. Spironolactone users exhibited higher risks of all-cause mortality [adjusted hazard ratio (aHR) 1.23; 95% confidence interval (CI) 1.11-1.37] and severe hyperkalemia (aHR 1.44; 95% CI 1.24-1.68) than nonusers. However, there was a lower risk of MACE (aHR 0.90; 95% CI 0.82-0.99), primarily due to a significant reduction in stroke risk (aHR 0.79; 95% CI 0.71-0.88). The risk of ESRD was similar between the two groups (aHR 1.09; 95% CI 0.85-1.38). Conclusions: In patients with CKD, spironolactone use was associated with a decreased risk of stroke but increased risks of severe hyperkalemia and all-cause mortality, while the risk of ESRD remained unchanged. Individualized clinical decision-making and appropriate dose adjustment are important to balance the potential benefits and risks associated with spironolactone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.